Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes



Rating:

Share or cite this content

Citations should be made in the following way:
T. Goos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), M. Vermant (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), R. Vos (Leuven, Belgium), B. Weynand (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium). Defining progression in non-IPF ILD. 2967

Member's Comments

No comment yet.

Related content which might interest you: ILD Source: Virtual Congress 2020 – Impact in children and in adults with premorbid respiratory disease (acute and long-term) Year: 2020 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 Coexistent COPD and ILD Source: Eur Respir Monogr 2015; 69: 109-120 Year: 2015 Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Predicting progression of RA-ILD using anti-CCP Source: International Congress 2015 – Connective tissue disorders Year: 2015 Delay in diagnosis of interstitial lung diseases (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016 Year: 2017 Elucidating progression of early cystic fibrosis lung disease Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017 Year: 2017 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Prognostic factors of interstitial lung disease (ILD) Source: Eur Respir J 2001; 18: Suppl. 33, 527s Year: 2001 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 COVID-19: Current Challenges in ILD Source: ERS webinar 2020: COVID-19: Current Challenges in ILD Year: 2020 Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Unclassifiable interstitial lung disease: a distinct entity with heterogeneous progression Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 Markers of pulmonary vascular compromise predict survival in interstitial lung disease (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003